212 related articles for article (PubMed ID: 21779792)
1. Gastrointestinal disturbances and their management in miglustat-treated patients.
Belmatoug N; Burlina A; Giraldo P; Hendriksz CJ; Kuter DJ; Mengel E; Pastores GM
J Inherit Metab Dis; 2011 Oct; 34(5):991-1001. PubMed ID: 21779792
[TBL] [Abstract][Full Text] [Related]
2. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
3. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Brand M; Muller A; Alsop J; van Schaik IN; Bembi B; Hughes D
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
[TBL] [Abstract][Full Text] [Related]
4. Miglustat: a review of its use in Niemann-Pick disease type C.
Lyseng-Williamson KA
Drugs; 2014 Jan; 74(1):61-74. PubMed ID: 24338084
[TBL] [Abstract][Full Text] [Related]
5. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.
Héron B; Valayannopoulos V; Baruteau J; Chabrol B; Ogier H; Latour P; Dobbelaere D; Eyer D; Labarthe F; Maurey H; Cuisset JM; de Villemeur TB; Sedel F; Vanier MT
Orphanet J Rare Dis; 2012 Jun; 7():36. PubMed ID: 22676771
[TBL] [Abstract][Full Text] [Related]
6. Dietary modifications in patients receiving miglustat.
Champion H; Ramaswami U; Imrie J; Lachmann RH; Gallagher J; Cox TM; Wraith JE
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S379-83. PubMed ID: 20844964
[TBL] [Abstract][Full Text] [Related]
7. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat.
Remenova T; Morand O; Amato D; Chadha-Boreham H; Tsurutani S; Marquardt T
Orphanet J Rare Dis; 2015 Jun; 10():81. PubMed ID: 26084276
[TBL] [Abstract][Full Text] [Related]
9. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
10. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β-galactosidases.
Amiri M; Naim HY
J Inherit Metab Dis; 2012 Nov; 35(6):949-54. PubMed ID: 22976762
[TBL] [Abstract][Full Text] [Related]
11. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
12. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
13. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
[TBL] [Abstract][Full Text] [Related]
14. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.
Machaczka M; Hast R; Dahlman I; Lerner R; Klimkowska M; Engvall M; Hägglund H
Ups J Med Sci; 2012 Mar; 117(1):28-34. PubMed ID: 22247978
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
[TBL] [Abstract][Full Text] [Related]
16. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
17. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
18. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Pérez-Poyato MS; Gordo MM; Marfa MP
Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297
[TBL] [Abstract][Full Text] [Related]
19. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.
Wraith JE; Vecchio D; Jacklin E; Abel L; Chadha-Boreham H; Luzy C; Giorgino R; Patterson MC
Mol Genet Metab; 2010 Apr; 99(4):351-7. PubMed ID: 20045366
[TBL] [Abstract][Full Text] [Related]
20. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
